{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpsychedelic-spotlight.simplecast.com%2Fepisodes%2Fjames-lanthier-ceo-mindset-pharma-_ymblX2t","width":444,"version":"1.0","type":"rich","title":"James Lanthier, CEO, Mindset Pharma","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/bebecc7d-bab7-47e7-be66-437a184e067d/a1662726-9a1b-4a51-ad9f-c4107aee5c9f/podcast-james-lanthier.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/57145efd-d701-4c24-940d-e1de86ea68ba\" height=\"200\" width=\"100%\" title=\"James Lanthier, CEO, Mindset Pharma\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Mindset Pharma’s CEO talks about new lead drug candidate MSP-1014, a potentially safer next generation psilocybin alternative used to assist people suffering from treatment-resistant depression."}